Pharmaceutical delivery device and method of preparation therefor
OwnerLance L. Goobermaninventor
Life of this patent
Estimating the term…
Abstract
The present invention provides an opiate antagonist implant which is an admixture of an opiate antagonist, in either acid or base form, and a pharmaceutically acceptable carrier. The admixture is uniformly compressed into a subcutaneously implantable pellet which is effective to release levels of the opiate antagonist over desired amounts of time when subcutaneously implanted in a patient to effectively inhibit the effects of a number of addictive drugs.
Claims40
An opiate antagonist subcutaneous implant comprising an admixture of an opiate antagonist, an steroidal anti-inflammatory agent and a pharmaceutically acceptable carrier.
A process of manufacturing an opiate antagonist subcutaneous implant comprising compressing a therapeutically effective amount of an opiate antagonist with an steroidal anti-inflammatory agent and a pharmaceutically acceptable carrier.
A process of manufacturing a naltrexone subcutaneous implant comprising the steps of:
- (a) providing a quantity of naltrexone;
- (b) providing a quantity of steroidal anti-inflammatory agent;
- (c) providing a pharmaceutically acceptable carrier;
- (d) admixing said anti-inflammatory agent with a pharmaceutically acceptable carrier and said naltrexone to form an admixture;
- and
- (e) applying uniform pressure to the admixture of step (d) in order to obtain a naltrexone implant in the form of a pellet.
A method of treating an opiate addicted patient for opiate addiction comprising administering subcutaneously to the patient an opiate antagonist implant comprising an admixture of an opiate antagonist, an steroidal anti-inflammatory agent, and a pharmaceutically acceptable carrier.
A method of using an opiate antagonist implant comprising an admixture of an opiate antagonist, an steroidal anti-inflammatory agent, and a pharmaceutically acceptable carrier, wherein said method comprises subcutaneously implanting said implant in a patient in need thereof.
A subcutaneous implant consisting essentially of an opiate antagonist, a steroidal anti-inflammatory agent and a carrier, wherein said opiate antagonist is a self-sustaining delivery mechanism for its own dissolution and delivery over time.
A method of increasing the duration of sustained release of therapeutically effective amounts of an opiate antagonist from an implant, comprising preparing an implant comprising an opiate antagonist, a steroidal anti-inflammatory agent and a carrier, and subcutaneously implanting the implant in a human in need thereof.
Dependencies are inferred from the claim text.